According to The Tribune, researchers at Mayo Clinic and the University of California San Francisco have shown that sorting patients based on the molecular makeup of brain tumors instead of tumor appearance is possible.
According to The Huffington Post, the AARP Forum on Family Caregiving held in Washington, DC, on July 8 spotlighted the largely ignored issue of family care and potential policies that will offer solutions and funding.
Tocagen Inc., a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead immuno-oncology product, Toca 511 & Toca FC, for the treatment of recurrent high grade glioma, which includes glioblastoma and anaplastic astrocytoma.
Neurosurgeon Albert Kim, MD, PhD, and his colleagues at the Washington University School of Medicine in St. Louis have pinpointed a protein relationship that may be responsible for halting the growth of new tumor cells.
ROCHESTER, Minn. — The molecular makeup of brain tumors can be used to sort patients with gliomas into five categories, each with different clinical features and outcomes, researchers at Mayo Clinic and the University of California San Francisco have shown. The finding could change the methods that physicians rely on to determine prognosis and treatment options. Previously, they relied on how patients’ tumors look under the microscope. The study is published online in the New England Journal of Medicine.
According to a research team at the Duke University Preston Robert Tisch Brain Tumor Center, a low dosage of a modified poliovirus therapy shows promising results for patients with a glioblastoma or GBM, a highly malignant brain tumor. Dosage findings of the first 20 patients in the Phase I trial were presented at the 2015 American Society of Clinical Oncology annual meeting in Chicago.